Trial Profile
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Everolimus (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 12 Sep 2015 Primary endpoint (Time to disease progression) has not been met according to the results published in the Urology.
- 12 Sep 2015 Results published in the Urology.
- 06 Sep 2013 Planned end date changed from 1 Apr 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.